The duration of adjuvant tamoxifen therapy
Authors:
- V. Craig JordanVJV. Craig Jordan
- 1 January 1998
- book chapter
- Published by Springer Nature
- Vol. 94, 181-193
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Different risk groups in node—negative breast cancer: Prognostic value of cytophotometrically assessed DNA, morphometry and textureInternational Journal of Cancer, 1995
- Gynecologic effects of tamoxifen and the association with endometrial carcinomaInternational Journal of Gynecology & Obstetrics, 1995
- Cardiac and Thromboembolic Morbidity Among Postmenopausal Women With Early Stage Breast Cancer in a Randomized Trial of Adjuvant TamoxifenJNCI: Journal of the National Cancer Institute, 1993
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifenJournal of Steroid Biochemistry, 1988
- The Christie Hospital Tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma - 7-yr resultsEuropean Journal of Cancer and Clinical Oncology, 1985
- BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUESThe Lancet, 1985
- Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applicationsBreast Cancer Research and Treatment, 1983
- Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model1980